Developing CAR-T Therapies Against Novel Cancer Antigens
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications
July 2025
November 2024
NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens
To develop robust mAb biologics, it is vital to fully characterize the protein, including its primary sequence, mutations, and important post-translational modifications